Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Minocycline Hydrochloride in Blood brain barrier defect: NCT04876638 Clinical Landscape Report 2026
16 October 2026
NCT04876638 clinical landscape for Blood brain barrier defect: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AXA1125 in Metabolic Dysfunction Associated Steatohepatitis: NCT04880187 Clinical Landscape Report 2026
16 October 2026
NCT04880187 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT04880031 Clinical Landscape Report 2026
16 October 2026
NCT04880031 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Hydroxycarbamide in Hematologic Diseases: PACTR202105884908295 Clinical Landscape Report 2026
16 October 2026
PACTR202105884908295 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Treprostinil in Idiopathic Pulmonary Fibrosis: NCT04905693 Clinical Landscape Report 2026
16 October 2026
NCT04905693 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nebivolol hydrochloride in Idiopathic Pulmonary Fibrosis: NCT04888728 Clinical Landscape Report 2026
16 October 2026
NCT04888728 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SRT-015 in Metabolic Dysfunction Associated Steatohepatitis: NCT04887038 Clinical Landscape Report 2026
16 October 2026
NCT04887038 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Monepantel in Motor Neuron Disease: NCT04894240 Clinical Landscape Report 2026
16 October 2026
NCT04894240 clinical landscape for Motor Neuron Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT04888715 Clinical Landscape Report 2026
16 October 2026
NCT04888715 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denifanstat in Metabolic Dysfunction Associated Steatohepatitis: NCT04906421 Clinical Landscape Report 2026
16 October 2026
NCT04906421 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
TERN-201 in Metabolic Dysfunction Associated Steatohepatitis: NCT04897594 Clinical Landscape Report 2026
16 October 2026
NCT04897594 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
XZP-5610 in Metabolic Dysfunction Associated Steatohepatitis: NCT04913090 Clinical Landscape Report 2026
16 October 2026
NCT04913090 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…